The chloroplast of Chlamydomonas reinhardtii and other microalgae represents an attractive new platform for the synthesis of recombinant therapeutics using synthetic biology (synbio) approaches. Transgenes can be designed in silico, assembled from validated DNA parts and inserted at precise and predetermined locations within the chloroplast genome to give stable synthesis of a desired recombinant protein. Numerous recent examples of different therapeutic proteins produced successfully in the C. reinhardtii chloroplast highlight the potential of this green alga as a simple, low-cost and benign host. Furthermore, some of the features of the alga may offer additional advantages over more-established microbial, mammalian or plant-based systems. These include efficient folding and accumulation of the product in the chloroplast; a lack of contaminating toxins or infectious agents; reduced downstream processing requirements; the possibility to make complex therapeutics such as immunotoxins; and the opportunity to use the whole alga as a low-cost oral vaccine. In this paper we review the current status of algal chloroplast engineering with respect to therapeutic proteins. We also consider future advances in synbio tools, together with improvements to recipient strains, which will allow the design of bespoke strains with high levels of productivity.
INTRODUCTION
Currently, the industrial biotechnology sector is almost exclusively based around the use of heterotrophic platforms (bacteria, yeasts, mammalian and insect cells) for the biosynthesis of pharmaceutical proteins, bioactive metabolites or other high-value products [1] . Nevertheless, the ever-increasing growth of the global bioeconomy and the need for sustainable alternatives to petrochemical-based products is catalyzing interest in the exploitation of alternative cell factories, including photosynthetic microalgae and cyanobacteria [2] . Microalgae represent significant untapped potential for bio-manufacturing because of the extreme biodiversity of the more than 70 000 extant species spread over the eukaryotic tree of life [3, 4] . However, exploitation of all but a handful of algal species is severely hindered by a paucity of molecular tools for efficient genetic engineering [2, 5] .
Of these species, the freshwater chlorophyte Chlamydomonas reinhardtii is perhaps the most advanced microalgal platform, with a suite of molecular tools for both nuclear and chloroplast transformation, and the ongoing development of synthetic biology strategies for strain engineering [6] . The chloroplast genetic system lends itself particularly well to synthetic biology since the genome is small (205 kb) and of low complexity (99 genes) [7] , and the precise integration of foreign DNA into any predetermined locus is readily achieved via homologous recombination [8] . Recently, there have been a number of reports describing the genetic engineering of the C. reinhardtii chloroplast to produce therapeutic proteins, with many shown to be active and effective in laboratory-based trials.
In this short review we outline the current status and merits of algal chloroplast transgenics, and survey the different classes of therapeutics being produced for either human or livestock applications. We also consider the future development of synthetic biology tools to accelerate the predictive design and creation of bespoke strains. A more detailed discussion of the history and wider applications of algal chloroplast engineering is given in several recent reviews [9] [10] [11] [12] .
THE ALGAL CHLOROPLAST AS A NEW BIO-FACTORY
The chloroplasts of plants and algal cells possess a small polyploid genome (termed the plastome) derived from the cyanobacterial progenitor of this organelle. The algal plastome is composed of~100-200 genes, most of which encode core components of the photosynthetic complexes and the chloroplast's transcription/translation apparatus. The genetic system reflects its bacterial ancestry and is essentially prokaryotic in nature, with a eubacterial-like RNA polymerase and 70S ribosome, and many genes arranged into co-transcribed units [13] . However, introns are present in some chloroplast genes, and the regulation of gene expression occurs largely at post-transcriptional steps (rather than at the transcriptional level) with numerous nuclear-encoded protein factors being imported into the chloroplast to mediate RNA processing, splicing and stabilization, and translation initiation [14] .
DNA transformation of the chloroplast was first reported in 1988 using the single-celled green alga, Chlamydomonas reinhardtii [15] . Since that time the tools and techniques for chloroplast genetic engineering of C. reinhardtii have advanced significantly [8, 16] . More recently, chloroplast transformation has been achieved for other microalgal species, including the green algae Haematococcus pluvialis and Dunaliella tertiolecta [17, 18] , the red alga Cyanidioschyzon merolae [19] and the diatom Phaeodactylum tricornutum [20] . However, the progress to date in the development of the algal chloroplast as a platform has almost exclusively focused on C. reinhardtii, with over 100 reports in the literature of the production of recombinant proteins in this species. Chloroplast transformation is also feasible for a number of plant species, with advanced genetic engineering technologies available for tobacco (Nicotiana tabacum) and several other plants such as tomato, potato and petunia [21] . Although plant chloroplasts represent an attractive low-cost and easily scalable platform for the synthesis of biopharmaceuticals [22] , there are fundamental challenges associated with the use of crop plants for drug production. These include the difficulties of ensuring good, rigorous manufacturing practices during glasshouse or field cultivation, and concerns regarding escape and contamination of food crops [23] . In contrast, a microalgal platform circumvents many of these issues, since these micro-organisms can be grown under tightly controlled, sterile and contained conditions in closed fermenter or photobioreactor systems. Furthermore, several microalgal species, including C. reinhardtii have generally recognized as safe (GRAS) status and are therefore considered to be free of harmful viral, prion or endotoxin contaminants, thereby simplifying the procedures for product purification. The safety of these species also offers the possibility of the topical application of a biopharmaceutical such as an anti-microbial protein using a crude cell lysate of the alga (e.g. formulated into a spray or cream), which would avoid costly investment in purification. Alternatively, it might be possible to use the whole alga for oral delivery (to animals, if not to humans) of vaccines, enzymes, or hormones -with the dried cells being exploited as a natural method of encapsulation and storage at room temperature that overcomes the need for a cold chain [24] .
Typically, transgenic DNA is introduced into the chloroplast by the bombardment of an algal lawn or plant tissue with DNA-coated gold microparticles. Alternative DNA delivery strategies include electroporation [25] or agitation of a DNA/cell suspension in the presence of glass beads [26] . DNA integration into the plastome occurs almost exclusively via homologous recombination between matching sequences on the incoming DNA and plastome sequence [8] . Consequently, transgenes can be precisely targeted to any locus by flanking the DNA with chloroplast sequences upstream and downstream of the target locus, as shown in Fig. 1 . Several selection strategies have been developed based on the use of bacterial antibiotic-resistance genes such as aadA and aphA6 [8] , but a superior selection strategy involves the rescue of a chloroplast mutant to phototrophy. As illustrated in Fig. 1 , this results in marker-free transformants in which the only foreign DNA in the plastome is the gene of interest [27, 28] . Expression of the gene is achieved by fusing the coding sequence to promoters and untranslated regions from highly expressed endogenous genes, such as the photosynthesis genes psaA and psbA. The efficiency of translation can be significantly improved by using a synthetic coding sequence that is optimized to match the AT-rich codon bias seen in chloroplast genes [9] . Biocontainment can also be built into the transgene by replacing several tryptophan codons (UGG) with the UGA stop codon and using an orthogonal tryptophan tRNA to recognize these internal stop codons in the chloroplast [29] . Although almost all of the transgenes that have been inserted into the C. reinhardtii chloroplast to date have been constituently expressed, regulation of transgene expression can be achieved using a vitamin-based system. Here, the expression of a nuclear gene encoding a factor essential for the translation of the chloroplast psbD gene is repressed by the addition of vitamin B 12 and thiamine to the medium. Any transgene fused to the psbD 5¢ UTR is therefore only translated in the absence of the vitamins [30] .
Using these molecular tools, over 100 different recombinant proteins have been successfully produced in the algal chloroplast. The reported yields are generally in the range of 0.1 to 5 % total soluble protein (TSP), although caution should be exercised when making comparisons, since the preparation of soluble extracts and the assay used for quantification differ between groups. A better measure is perhaps protein yield per gramme of dried biomass [31] . Whilst such levels are below those of established recombinant platforms, new synthetic biology approaches (see below) and moleculargenetics strategies based on our understanding of chloroplast gene regulation in C. reinhardtii are now leading to significant improvements in yield.
BIOPHARMACEUTICALS MADE IN THE C. REINHARDTII CHLOROPLAST
A review of the literature identified over 40 different therapeutic proteins that have been successfully produced in C. reinhardtii chloroplasts, with many shown to be bioactive, as summarized in Table 1 . In most cases these are single subunit proteins and therefore involve the introduction of only a single transgene, although there have been a few examples of multigenic engineering of the plastome [32, 33] . To date, all of the therapeutic proteins that have been reported are soluble and accumulate in the chloroplast stroma, save for a single report of the targeting of an antibody fragment to the thylakoid lumen [34] , although membrane-anchored proteins have been successfully produced in the algal chloroplast [35] .
Subunit vaccines
Edible microalgae such as C. reinhardtii are attractive systems for oral delivery of protein vaccines. This is especially the case for farmed animals such as fish and poultry, where alternative vaccination strategies such as the injection of a purified vaccine are impractical or prohibitively expensive given the small size and low value of the individual animal. As detailed in Table 1 , antigens from viral, bacterial and malarial parasite pathogens have been produced in the algal chloroplast, and in many of these cases an immunogenic response has been demonstrated in model animals. In several studies, a protein adjuvant (cholera toxin B subunit: CTB) has been fused to the N-terminus of the antigen. CTB assembles into a pentameric structure and can serve as an effective mucosal adjuvant by binding GM1 ganglioside receptors on gut epithelial cells. For those vaccines aimed at the aquaculture, poultry and livestock industries, the whole dried algae could be formulated into the animal feed. For the malarial vaccines, the need for very low-cost and simple production technologies for any treatment in developing countries may ultimately overcome the current strict regulations for vaccine purification and lead to the use of such whole-cell preparations as oral therapeutics [36] . Importantly, several studies have shown that the chloroplast-produced vaccines in lyophilized algae remain stable and active at room temperature over extended periods. For example, Dreesen et al. [37] showed that their CTB-D2 vaccine was stable for more than 1.5 years at room temperature, and Gregory et al. [38] showed that their CTB-Pfs25 vaccine remained active for over 6 months at 22 C (although activity was reduced at 37 C). The lack of a requirement for a cold-chain would obviously reduce the complexity and cost of vaccine distribution. Drying the algae also serves to bioencapsulate the vaccine within multiple layers (the double membrane of the chloroplast, the cell membrane and the cell wall), thereby helping to protect the vaccine from oxidation during storage, and degradation within the animal stomach during delivery to the gut epithelium. Furthermore, it is possible that the components of the algal cell wall could act as an effective mucosal adjuvant [39] . Marker-free strategy for introducing transgenes into the C. reinhardtii chloroplast. The gene of interest (GOI) is codon-optimized to match chloroplast genes, and assembled into a transformation construct using a 'one-step' method such as Golden Gate or Gibson assembly. The left and right arms are chloroplast DNA parts that ensure insertion into a specific intergenic region via homologous recombination between the arms and the recipient plastome. One of the arms carries a wild-type copy of a gene that is essential for photosynthesis, and selection is based on the repair of a mutated form of this gene (indicated with an 'X') in the photosynthesis-deficient (P/S-) recipient strain. The resulting transformant is therefore restored to phototrophy (P/S+), with only the GOI being introduced into the plastome. 
Antibodies and immunotoxins
Complex proteins such as monoclonal antibodies (mAbs) that contain multiple disulphide bonds are difficult to produce in prokaryotes and therefore have to be made using eukaryotic platforms [40] . Currently, almost all marketed antibodies are produced in mammalian cell cultures, and are therefore expensive and limited in availability [41] . Although the chloroplast does not possess the machinery for the glycosylation of proteins, work by the Mayfield's group has shown that the algal chloroplast is capable of correctly folding and assembling aglycosylated antibodies that are able to bind their target. An early study [42] produced a mAb against glycoprotein D of the herpes simplex virus (HSV) as a large single chain in which the variable region of the light chain was fused via a linker to the IgA heavy chain. This protein accumulated as a soluble protein that could form a dimer linked by disulphide bonds and was shown to bind the HSV glycoprotein in vitro. Subsequently, Tran et al. [33] demonstrated that a mAb comprising separate heavy and light chains that were co-expressed in the chloroplast assembled correctly into a functional tetramer of two heavy chains and two light chains held together by multiple disulphide bonds. The mAb was directed against the PA83 antigen of Bacillus anthracis and the study showed that the chloroplast-produced mAb bound to the antigen with a similar affinity to a mAb produced in a mammalian system. The Mayfield group extended their studies to show that immunotoxins -fusion proteins comprising antibodies linked to cytotoxic proteins that have applications in cancer treatment -can also be produced in the algal chloroplast. Production of such cytotoxic proteins in eukaryotic hosts such as CHO cells or yeast is not feasible because of the lethal effect of the toxin on the cytosolic translation apparatus, whereas production in prokaryotic systems is challenging because of the difficulty of folding and assembling such complex molecules. In two impressive papers, the group achieved the synthesis of immunotoxins comprising a single-chain antibody recognizing the CD22 surface receptor from B-cells fused either to domain II and III of exotoxin A from Pseudomonas aeruginosa [43] or to the ribosome-inactivating protein, gelonin, from Gelonium multiflorm [44] . Both immunotoxins were capable of specifically binding B-cells in vitro, and in the case of the immunotoxin exotoxin A the life span of mice implanted with a human B-cell tumor was extended. This work showed that the algal chloroplast possesses the machinery necessary to fold and assemble complex eukaryotic proteins, while the 70S ribosomes are unaffected by the toxic proteins and the organelle is able to completely contain the protein, preventing any inhibitory effect on the host's cytosolic ribosomes. The chloroplast therefore presents an attractive sub-cellular compartment for efficient production of these highly complex therapeutics.
Other therapeutic proteins
As detailed in Table 1 , numerous other classes of therapeutic proteins have been successfully produced in the C. reinhardtii chloroplast and shown to be biologically active. These include hormones such as human growth hormone [28] , anti-hypertensive peptides [45] , cancer therapeutics [46] , antibody mimics [47] , autoantigens [48] , wound-healing factors [47] and anti-bacterial enzymes [31] . These examples serve to illustrate the potential of the chloroplast as a platform for a wide variety of recombinants. However, two areas where the GRAS benefits of microalgae such as C. reinhardtii could be particularly exploited are allergenspecific immunotherapy (AIT) and the delivery of gut-active proteins to livestock. Treatment of food allergies such as peanut allergy using AIT represents a promising strategy, with the allergen delivered via oral, sublingual or epicutaneous routes. However, the high risk of adverse side-effects from the complex protein mix in peanut extracts means that immunotherapy using such extracts is not recommended in clinical practice. In contrast, recombinant allergens can be purified without concern for contamination by cross-reactive peanut proteins, and are therefore an attractive alternative to native allergens for immunotherapy and allergy diagnostics [49] . Furthermore, the recombinant proteins can be modified to reduce the severity of the allergic response. Gregory et al. [50] showed that major peanut allergens produced in C. reinhardtii conferred protection from peanut-triggered anaphylaxis in a mouse model. This study will hopefully pave the way for human trials of AIT using oral delivery of the recombinant algae.
Mammary-associated serum amyloid (M-SAA) is a component of mammalian colostrum and induces mucin synthesis in gut epithelial cells, resulting in increased protection of newborns against bacterial infections in the intestine [51] . Algal-produced M-SAA provided in the feed could provide this protective agent for newborn mammals that lack a source of colostrum, serving as a prophylactic against infection. Manuell et al. [52] showed that M-SAA produced in C. reinhardtii was able to stimulate mucin production in human gut epithelial cell lines. Another feed additive that has significant health and economic benefits in agriculture is phytase. In plant-derived animal feed, nearly 80 % of the total phosphorus content is stored as phytate. However, phytate is poorly digested by monogastric animals such as swine, poultry and fish, as they lack the hydrolytic enzyme phytase. In addition, phytate also chelates important dietary minerals and essential amino acids. Therefore, dietary supplementation with bioavailable phosphate and exogenous phytases are required to achieve optimal animal growth [53] . Two separate studies have produced recombinant phytases in C. reinhardtii [54, 55] , with the earlier study demonstrating that dried algal biomass fed to broiler chicks significantly reduced phytate excretion, and the latter study calculating that the costs of production in microalgae are comparable to those for commercial supplies of phytase. It is possible to envisage further cost savings in, for example, pig feed by 'pyramiding' different gut-active proteins such that a single alga produces multiple recombinant products such as phytase, M-SAA, vaccines and anti-bacterials.
EMERGING SYNTHETIC BIOLOGY APPROACHES
Currently, most recombinant expression in the algal chloroplast involves single-gene constructs created using conventional restriction enzyme-based cloning approaches. This limits the rate at which new transgenic lines can be produced and tested, and in particular, how many different permutations of constructs (different promoters, coding variants, regulatory elements, etc.) can be evaluated. We are now starting to see the application of synthetic biology principles to plastome engineering with the adoption of assembly standards such as Golden Gate and the creation of libraries of validated DNA parts that allow rapid one-step assembly of all the parts [27, 56, 57] . In the near future, we may see much more ambitious design strategies that involve extensive redesign of the plastome in silico such that large tracts of non-essential DNA are removed [58] , essential endogenous genes are refactored into functional clusters [59] and multiple transgenes are engineered into different loci. The assembly and delivery of such synthetic genomes is technically feasible, as shown by O'Neill et al. [60] , who demonstrated that the entire C. reinhardtii plastome could be assembled in yeast and transformed into C. reinhardtii by microparticle bombardment. The challenge is to develop selection strategies that allow the clean replacement of the endogenous plastome with the synthetic version without undesirable recombination events between the two resulting in the creation of chimeric plastomes [60] .
Another challenge is to improve the product yield significantly through the use of synthetic cis elements to drive expression. Currently, the promoter and 5¢UTR used to express transgenes are derived from endogenous photosynthetic genes. In some cases, expression levels can be improved by using the stronger promoter from the gene for the 16S ribosomal RNA fused to the 5¢UTR of a photosynthetic gene [27, 61] . However, more often it is the performance of the 5¢UTR that is the bottleneck [62] , with the efficiency of translation constrained by either the same feedback regulation that prevents the over-accumulation of individual photosynthetic subunits in the absence of their assembly partners (so-called 'control by epistasy of synthesis'), or by competition with the corresponding endogenous gene transcript for trans-acting factors that are required for transcript stability or translation, but are present in limiting concentration in the chloroplast [63] . The strategies to overcome this involve either replacement of the 5¢UTR of the endogenous gene with that from another photosynthetic gene [64] or, more elegantly, the development of synthetic variants of the 5¢UTR that are no longer subject to these limitations and therefore enable improved expression of the transgene [65] . Further studies into the design of synthetic promoters and UTRs, combined with improved knowledge of codon optimization rules, will advance the average recombinant protein yield from the current value of 1 % TSP to the >10 % level required for a commercial platform.
SUMMARY AND PERSPECTIVES
The microalgal chloroplast has clear potential as a novel industrial production platform for biopharmaceuticals. The continued development of synthetic biology tools for chloroplast engineering of C. reinhardtii will strengthen this potential by accelerating the creation of designer transgenic lines yielding high levels of the target protein. However, this increase in yield needs to be coupled with improvements in phototrophic algal biomass production in order to make the platform commercially competitive. Such improvements will come from a combination of media optimization [66] , improvements in photobioreactor (PBR) design [67] and strain domestication, such as selection for reduced light-antenna mutants that show higher productivity in PBRs as a consequence of greater light penetration [68] . Alternatively, it might be more cost-effective to switch to mixotrophic production in PBRs, or heterotrophic cultivation in fermenters, where much higher biomass productivity can be achieved [69] . In the case of C. reinhardtii, acetate is used as the fixed carbon source, although strain engineering could enable the alga to be cultivated using glucose or sucrose as the carbon source [70] . Finally, the development of chloroplast transformation technology for other GRAS species, such as Dunaliella salina, Chlorella vulgaris and Haematococcus pluvialis, which are already grown commercially, will provide opportunities for larger-scale and lowercost production of therapeutic proteins in algae. 
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